ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA

ACTG A5030-缬更昔洛韦预防巨细胞病毒 (CMV) 病毒血症

• 批准号: 7377767
• 负责人: THOMAS A CAMPBELL
• 金额: $ 3.47万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377767
• 关键词: ACTG; A5030; VALGANCICLOVIR; PRE; EMPTIVE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to find out whether treatment with valganciclovir is safe and effective in preventing CMV organ damage in persons with HIV infection at risk for CMV disease. Eligible subjects will be CMV seropositive, currently receiving no CMV prophylaxis, with no evidence of CMV end organ disease, have a CD4 cell count <100 cells/ mm3, and a plasma HIV RNA >400 copies/mL. Subjects must either have, at time of screening, been receiving antiretroviral therapy continuously for >3 months or not be receiving antiretroviral therapy and not planning to initiate antiretroviral therapy for at least 3 months after entering the study.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。该研究的目的是确定缬更昔洛韦治疗是否安全有效，可预防有CMV疾病风险的HIV感染者的CMV器官损伤。合格的受试者将是CMV血清阳性的，目前未接受CMV预防，没有CMV终末器官疾病的证据，CD 4细胞计数<100个细胞/mm 3，血浆HIV RNA >400拷贝/mL。受试者必须在筛选时已经连续接受抗逆转录病毒治疗>3个月，或者在进入研究后至少3个月内没有接受抗逆转录病毒治疗并且不计划开始抗逆转录病毒治疗。